Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration
Go back to Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration| (NASDAQ: KYMR) | Delayed: 99.45 +9.02 (9.97%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $90.43 | 52 Week High | $ | |||
| Open | $92.84 | 52 Week Low | $ | |||
| Day High | $105.00 | P/E | N/A | |||
| Day Low | $91.74 | EPS | $ | |||
| Volume | 2,891,279 | |||||
